- Information
- AI Chat
Med- mifepristone - OB active learning template
Nursing LVN (VN 200)
Unitek College
Preview text
PURPOSE OF MEDICATION
ACTIVE LEARNING TEMPLATE: Medication
Complications
CNS: dizziness, fainting, headache, weakness. GI: abdominal pain, diarrhea, nausea, vomiting. GU: uterine bleeding, uterine cramping, rup
Medication Administration
Inserted vaginally. Dosage is 10 mg of dinoprostone designed to be gradually released (approximately 0 mg/hr) over 12 hours. Insert is p
c pregnancy; Undiagnosed adnexal mass; Chronic adrenal failure; Concurrent long- term corticosteroid therapy; Bleeding disorders or concurrent anticoagulant therapy; In
hromycin. Blood levels and effects may be ↓ by rifampin, dexamethasone, phenytoin, phenobarbital, and carbamazepine. Mifepristone may ↓ metabolism and ↑ effects of other drugs metabo
including some agents used during general anesthesia. : Blood levels and effects may be ↓ by St. John's wort. Drug-Food: Blood levels and effects may be ↑ by grapefruit juice.
Evaluation of Medication Effectiveness
Effectiveness medical termination of intrauterine pregnancy
STUDENT NAME Baoquynh Nguyen
MEDICATION: Mifepristone REVIEW MODULE CHAPTER CATEGORY
CLASS Abortifacients
Expected Pharmacological Action
Antagonizes endometrial and myometrial effects of
progesterone. Sensitizes the myometrium to contraction-
inducing activity of prostaglandins..
Therapeutic Use
Termination of pregnancy.
Nursing Interventions
Assess dizziness, fainting, and weakness that might affect gait, balance, and other functional activities. Report persistent balance problems and functional limitations to the physician, and caution the patient and family/caregivers to guard against falls and trauma..
Client Education
Instruct patient to notify health care professional immediately if she develops weakness, nausea, vomiting, diarrhea, with or without abdominal pain or fever more than 24 hr after taking mifepristone; may indicate life-threatening sepsis.
Inform patient that vaginal bleeding and uterine cramping will probably occur. Bleeding or spotting occurs for an average of 9–16 days, but may continue for more than 30 days. Instruct patient to report any severe or unusual cramping, bleeding, or pelvic pain that extends beyond the expected time periods.
ACTIVE LEARNING TEMPLATES TherapeuTic procedure A
Med- mifepristone - OB active learning template
Course: Nursing LVN (VN 200)
University: Unitek College
